AlphaFold: Half a Decade of Influence
Here’s the rewritten content without external promotional call-to-actions:
Increasing speed of discovery
Cyril Zipfel, professor of Molecular & Cellular Plant Physiology at the University of Zurich and Sainsbury Lab, observed significant reductions in research timelines. They utilized AlphaFold alongside comparative genomics to gain insights into how plants perceive environmental changes, paving the way for more resilient crops. AlphaFold has been cited in over 35,000 papers, with more than 200,000 incorporating elements of AlphaFold 2 in their methodologies, thereby enhancing the quality of the research being produced.
An independent analysis of AlphaFold 2’s impact, carried out by the Innovation Growth Lab, indicates that researchers using AlphaFold 2 experience an increase of over 40% in submitting novel experimental protein structures. These structures are more likely to be distinct from known forms, promoting exploration in uncharted scientific areas. Additionally, research associated with AlphaFold 2 is twice as likely to be cited in clinical articles and significantly more likely to receive citations in patents compared to typical works in structural biology.
A new era of digital biology
One remarkable example of AlphaFold's impact is Isomorphic Labs – an AI drug discovery company established in 2021 when the breakthrough model showed sufficient power for rational drug design applications. Isomorphic Labs has developed a unified drug design engine that aims to transform the process of designing new medicines and accelerate scientific discovery, aspiring to eventually address all diseases.
In collaboration with Isomorphic Labs, we developed AlphaFold 3, which provides an unprecedented view into cellular interactions, anticipated to transform drug discovery and herald an era of "digital biology." This model is designed to predict the structures and interactions of all biological molecules—not just proteins, but also DNA, RNA, and ligands (the small molecules that constitute most drugs). It can generate the joint 3D structures of entire molecular complexes, offering a holistic perspective on how potential drug molecules bind to target proteins or interact with genetic material.
The AlphaFold Server is equipping non-commercial researchers globally to leverage this technology, enhancing their ability to formulate and test new hypotheses. To date, it has facilitated the production of over 8 million folds—predictions of structures and interactions—for thousands of researchers worldwide.
